Vertebrate animal models of glioma: Understanding the mechanisms and developing new therapies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 1, 2013, Pages 158-165

  Chen, Leon ^a   Zhang, Yuqing ^b   Yang, Jingxuan ^a   Hagan, John P ^a   Li, Min ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Animal model; Brain tumor; Cancer therapy; Tumorigenesis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

CANCER RESEARCH; CARCINOGENESIS; CYCLIN DEPENDENT KINASE INHIBITOR 2A GENE; DISEASE MODEL; DOG; EPIDERMAL GROWTH FACTOR GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE MUTATION; GENETIC ENGINEERING; GLIOBLASTOMA; NONHUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DOGS; GLIOMA; HUMANS; MICE; RATS; VERTEBRATES;

EID: 84878139953     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.04.003     Document Type: Review

References (82)

1. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2001, 2:120-129.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
3. Brat D.J., Van Meir E.G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Invest. 2004, 84:397-405.
4. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001, 15:1311-1333.
5. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schuler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lutolf U.M., Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64:6892-6899.
6. Lathrop A.E., Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. The Journal of cancer research 1916, 1:1-19.
7. Dai C., Holland E.C. Glioma models. Biochim. Biophys. Acta 2001, 1551:M19-M27.
8. Salvati M., Ramundo Orlando E., Causo R., Innocenzi G., Capone R., Cosentino F., Cosentino F. Tumors of the central nervous system induced by ionizing radiation. Update on their pathology and presentation of a case. G. Ital. Oncol. 1990, 10:15-18.
9. Kaye A.H., Morstyn G., Gardner I., Pyke K. Development of a xenograft glioma model in mouse brain. Cancer Res. 1986, 46:1367-1373.
10. Ponten J. Neoplastic human glia cells in culture. In Human Tumor Cells, in Vitro 1975, 175-185.
11. Camphausen K., Purow B., Sproull M., Scott T., Ozawa T., Deen D.F., Tofilon P.J. Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. Cancer Res. 2005, 65:10389-10393.
12. Jacobs V.L., Valdes P.A., Hickey W.F., De Leo J.A. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro 2011, 3:e00063.
13. Radaelli E., Ceruti R., Patton V., Russo M., Degrassi A., Croci V., Caprera F., Stortini G., Scanziani E., Pesenti E., Alzani R. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol. Histopathol. 2009, 24:879-891.
14. Candolfi M., Curtin J.F., Nichols W.S., Muhammad A.G., King G.D., Pluhar G.E., McNiel E.A., Ohlfest J.R., Freese A.B., Moore P.F., Lerner J., Lowenstein P.R., Castro M.G. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol 2007, 85:133-148.
15. de Vries N.A., Beijnen J.H., van Tellingen O. High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat. Rev. 2009, 35:714-723.
16. Finkelstein S.D., Black P., Nowak T.P., Hand C.M., Christensen S., Finch P.W. Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery 1994, 34:136-143.
17. Zhao Y., Xiao A., diPierro C.G., Carpenter J.E., Abdel-Fattah R., Redpath G.T., Lopes M.B., Hussaini I.M. An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am. J. Pathol. 2010, 176:3032-3049.
18. Giannini C., Sarkaria J.N., Saito A., Uhm J.H., Galanis E., Carlson B.L., Schroeder M.A., James C.D. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005, 7:164-176.
19. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
20. Bello L., Giussani C., Carrabba G., Pluderi M., Lucini V., Pannacci M., Caronzolo D., Tomei G., Villani R., Scaglione F., Carroll R.S., Bikfalvi A. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2002, 8:3539-3548.
21. Brinster R.L., Chen H.Y., Messing A., van Dyke T., Levine A.J., Palmiter R.D. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984, 37:367-379.
22. Fomchenko E.I., Holland E.C. Mouse models of brain tumors and their applications in preclinical trials. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12:5288-5297.
23. Fisher G.H., Orsulic S., Holland E., Hively W.P., Li Y., Lewis B.C., Williams B.O., Varmus H.E. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 1999, 18:5253-5260.
24. Danks R.A., Orian J.M., Gonzales M.F., Tan S.S., Alexander B., Mikoshiba K., Kaye A.H. Transformation of astrocytes in transgenic mice expressing SV40 T antigen under the transcriptional control of the glial fibrillary acidic protein promoter. Cancer Res. 1995, 55:4302-4310.
25. Chen J., Tobin G.J., Pipas J.M., Van Dyke T. T-antigen mutant activities in vivo: roles of p53 and pRB binding in tumorigenesis of the choroid plexus. Oncogene 1992, 7:1167-1175.
26. Weissenberger J., Steinbach J.P., Malin G., Spada S., Rulicke T., Aguzzi A. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 1997, 14:2005-2013.
27. Ding H., Roncari L., Shannon P., Wu X., Lau N., Karaskova J., Gutmann D.H., Squire J.A., Nagy A., Guha A. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 2001, 61:3826-3836.
28. Xiao A., Wu H., Pandolfi P.P., Louis D.N., Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 2002, 1:157-168.
29. Huang P.H., Xu A.M., White F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2009, 2:re6.
30. Hatanpaa K.J., Burma S., Zhao D., Habib A.A. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12:675-684.
31. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990, 87:8602-8606.
32. Schlegel J., Merdes A., Stumm G., Albert F.K., Forsting M., Hynes N., Kiessling M. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int. J. Cancer 1994, 56:72-77.
33. Zhu Y., Parada L.F. The molecular and genetic basis of neurological tumours. Nat. Rev. Cancer 2002, 2:616-626.
34. Holland E.C. A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol. Pathol. 2000, 28:171-177.
35. Ding H., Shannon P., Lau N., Wu X., Roncari L., Baldwin R.L., Takebayashi H., Nagy A., Gutmann D.H., Guha A. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res. 2003, 63:1106-1113.
36. Weiss W.A., Burns M.J., Hackett C., Aldape K., Hill J.R., Kuriyama H., Kuriyama N., Milshteyn N., Roberts T., Wendland M.F., DePinho R., Israel M.A. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 2003, 63:1589-1595.
37. Zhu H., Acquaviva J., Ramachandran P., Boskovitz A., Woolfenden S., Pfannl R., Bronson R.T., Chen J.W., Weissleder R., Housman D.E., Charest A. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2712-2716.
38. Chu E.C., Tarnawski A.S. PTEN regulatory functions in tumor suppression and cell biology. Med. Sci. Monit. 2004, 10:RA235-RA241.
39. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
40. Simpson L., Parsons R. PTEN: life as a tumor suppressor. Exp. Cell Res. 2001, 264:29-41.
41. Zheng H., Ying H., Yan H., Kimmelman A.C., Hiller D.J., Chen A.J., Perry S.R., Tonon G., Chu G.C., Ding Z., Stommel J.M., Dunn K.L., Wiedemeyer R., You M.J., Brennan C., Wang Y.A., Ligon K.L., Wong W.H., Chin L., DePinho R.A. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008, 455:1129-1133.
42. Network T.C.G.A.R. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
43. Tohma Y., Gratas C., Biernat W., Peraud A., Fukuda M., Yonekawa Y., Kleihues P., Ohgaki H. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 1998, 57:684-689.
44. Ichimura K., Ohgaki H., Kleihues P., Collins V.P. Molecular pathogenesis of astrocytic tumours. J. Neurooncol 2004, 70:137-160.
45. Koul D., Parthasarathy R., Shen R., Davies M.A., Jasser S.A., Chintala S.K., Rao J.S., Sun Y., Benvenisite E.N., Liu T.J., Yung W.K. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 2001, 20:6669-6678.
46. Xiao A., Yin C., Yang C., Di Cristofano A., Pandolfi P.P., Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res. 2005, 65:5172-5180.
47. Hu X., Pandolfi P.P., Li Y., Koutcher J.A., Rosenblum M., Holland E.C. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005, 7:356-368.
48. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 2000, 25:55-57.
49. Uhrbom L., Dai C., Celestino J.C., Rosenblum M.K., Fuller G.N., Holland E.C. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 2002, 62:5551-5558.
50. Wei Q., Clarke L., Scheidenhelm D.K., Qian B., Tong A., Sabha N., Karim Z., Bock N.A., Reti R., Swoboda R., Purev E., Lavoie J.F., Bajenaru M.L., Shannon P., Herlyn D., Kaplan D., Henkelman R.M., Gutmann D.H., Guha A. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res. 2006, 66:7429-7437.
51. Kwon C.H., Zhao D., Chen J., Alcantara S., Li Y., Burns D.K., Mason R.P., Lee E.Y., Wu H., Parada L.F. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 2008, 68:3286-3294.
52. Ivanchuk S.M., Mondal S., Dirks P.B., Rutka J.T. The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J. Neurooncol 2001, 51:219-229.
53. Ranuncolo S.M., Varela M., Morandi A., Lastiri J., Christiansen S., Bal de Kier Joffe E., Pallotta M.G., Puricelli L. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J. Neurooncol 2004, 68:113-121.
54. Nishikawa R., Furnari F.B., Lin H., Arap W., Berger M.S., Cavenee W.K., Huang H.J.Su. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res. 1995, 55:1941-1945.
55. Ichimura K., Schmidt E.E., Goike H.M., Collins V.P. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072.
56. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
57. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
58. Lang F.F., Miller D.C., Koslow M., Newcomb E.W. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 1994, 81:427-436.
59. Reilly K.M., Loisel D.A., Bronson R.T., McLaughlin M.E., Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 2000, 26:109-113.
60. Sorensen S.A., Mulvihill J.J., Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N. Engl. J. Med. 1986, 314:1010-1015.
61. Gutmann D.H. New insights into the neurofibromatoses. Curr. Opin. Neurol. 1994, 7:166-171.
62. Zhu Y., Guignard F., Zhao D., Liu L., Burns D.K., Mason R.P., Messing A., Parada L.F. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005, 8:119-130.
63. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8:147-156.
64. Louis D.N. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. 2006, 1:97-117.
65. Warnke P.C., Molnar P., Lapin G.D., Kuruvilla A., Groothuis D.R. The effects of dexamethasone on transcapillary transport in experimental brain tumors: II. Canine brain tumors. J. Neurooncol 1995, 25:29-38.
66. Whelan H.T., Clanton J.A., Wilson R.E., Tulipan N.B. Comparison of CT and MRI brain tumor imaging using a canine glioma model. Pediatr. Neurol. 1988, 4:279-283.
67. Dobson J.M., Samuel S., Milstein H., Rogers K., Wood J.L. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J. Small Anim. Pract. 2002, 43:240-246.
68. Snyder S.A., Dewhirst M.W., Hauck M.L. The role of hypoxia in canine cancer. Vet. Comp. Oncol. 2008, 6:213-223.
69. Keller E.T., Madewell B.R. Locations and types of neoplasms in immature dogs: 69 cases (1964-1989). J. Am. Vet. Med. Assoc. 1992, 200:1530-1532.
70. Heidner G.L., Kornegay J.N., Page R.L., Dodge R.K., Thrall D.E. Analysis of survival in a retrospective study of 86 dogs with brain tumors. J. Vet. Intern. Med. 1991, 5:219-226.
71. Gavin P.R., Fike J.R., Hoopes P.J. Central nervous system tumors. Semin. Vet. Med. Surg. (Small Anim.) 1995, 10:180-189.
72. Ingram M., Buckwalter J.G., Jacques D.B., Freshwater D.B., Abts R.M., Techy G.B., Miyagi K., Shelden C.H., Rand R.W., English L.W. Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol. Res. 1990, 12:265-273.
73. Stubbs J.B., Frankel R.H., Schultz K., Crocker I., Dillehay D., Olson J.J. Preclinical evaluation of a novel device for delivering brachytherapy to the margins of resected brain tumor cavities. J. Neurosurg. 2002, 96:335-343.
74. Chauvet A.E., Kesava P.P., Goh C.S., Badie B. Selective intraarterial gene delivery into a canine meningioma. J. Neurosurg. 1998, 88:870-873.
75. Dickinson P.J., LeCouteur R.A., Higgins R.J., Bringas J.R., Roberts B., Larson R.F., Yamashita Y., Krauze M., Noble C.O., Drummond D., Kirpotin D.B., Park J.W., Berger M.S., Bankiewicz K.S. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J. Neurosurg. 2008, 108:989-998.
76. Stoica G., Lungu G., Martini-Stoica H., Waghela S., Levine J., Smith R. Identification of cancer stem cells in dog glioblastoma. Vet. Pathol. 2009, 46:391-406.
77. Higgins R.J., Dickinson P.J., LeCouteur R.A., Bollen A.W., Wang H., Corely L.J., Moore L.M., Zang W., Fuller G.N. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J. Neurooncol 2010, 98:49-55.
78. Kirkness E.F., Bafna V., Halpern A.L., Levy S., Remington K., Rusch D.B., Delcher A.L., Pop M., Wang W., Fraser C.M., Venter J.C. The dog genome: survey sequencing and comparative analysis. Science 2003, 301:1898-1903.
79. Hansen K., Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur. J. Cancer 2004, 40:858-880.
80. Feitsma H., Kuiper R.V., Korving J., Nijman I.J., Cuppen E. Zebrafish with mutations in mismatch repair genes develop neurofibromas and other tumors. Cancer Res. 2008, 68:5059-5066.
81. Read R.D., Cavenee W.K., Furnari F.B., Thomas J.B. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet. 2009, 5:e1000374.
82. Witte H.T., Jeibmann A., Klambt C., Paulus W. Modeling glioma growth and invasion in Drosophila melanogaster. Neoplasia 2009, 11:882-888.